Enzalutamide (MDV3100)

目录号:S1250 中文名称:恩杂鲁胺

仅限科研使用

Enzalutamide (MDV3100)是一种androgen-receptor (AR)拮抗剂,在 LNCaP细胞中IC50为36 nM。研究证明 Enzalutamide 可促进自噬。

Enzalutamide (MDV3100) Chemical Structure

CAS: 915087-33-1

规格 价格 库存 购买数量
10mM (1mL in DMSO) RMB 2444.41 现货
RMB 1221.51 现货
RMB 2224.43 现货
RMB 6297.61 现货
大包装 有超大折扣
大剂量询单有大折扣!

今日订购,明日送达 全国免运费 分装免费 分装成小规格产品(单支最小为1mg)
如1支10mg产品可分装为10支1mg产品

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Enzalutamide (MDV3100)发表文献418篇:

产品安全说明书

Androgen Receptor抑制剂选择性比较

相关Androgen Receptor产品

生物活性

产品描述 Enzalutamide (MDV3100)是一种androgen-receptor (AR)拮抗剂,在 LNCaP细胞中IC50为36 nM。研究证明 Enzalutamide 可促进自噬。
靶点
Androgen Receptor [1]
(LNCaP cells)
36 nM
体外研究

Enzalutamide是雄激素受体(AR)拮抗剂,IC50为36 nM。在加入16β-[18F]氟-5α-DHT (18-FDHT)的竞争性实验中发现作用于AR时Enzalutamide比bicalutamide具有更高的亲和力。而Enzalutamide作用于LNCaP/AR(AR-过量表达)前列腺细胞时没有效果。在亲本LNCaP细胞中,Enzalutamide抑制前列腺特异性抗原(PSA)和跨膜丝氨酸蛋白酶2(TMPRSS2) 的产生,及抑制它们与合成的雄激素R1881 结合。Enzalutamide可抑制突变AR蛋白(W741C, 741位上的Trp突变为Cys)的翻译活性。[1]MDV310也阻断核转位和配位受体复合物招募辅激活因子。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human LNCAP NWnHXIMzS3m2b4TvfIlkKEG|c3H5 M2TNfVch\GG7cx?= NWjFN|J4QTVnIFX0U2g> M2fCd2lEPTB;NT6xNkDPxE1? NGi4Zo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{exN|U3Pyd-MkO3NVM2Pjd:L3G+
human LNCAP MXjGeY5kfGmxbjDBd5NigQ>? MoTjNUDPxE1? M13iRmROW09? NFXQcGxKdmirYnn0d{Bxem:|dHH0[UB{eGWlaX\pZ{BidnSrZ3XuJJNm[3KndHnvckBqdiCqdX3hckBNVkODUDDj[YxteyCneIDy[ZN{cW6pIHHu[JJw\2WwIILlZ4VxfG:{IHH0JFExOC1zMECwcm0> M3ThRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMkG4O|E4Lz5{MEKxPFcyPzxxYU6=
VCaP MVrGeY5kfGmxbjDBd5NigQ>? NVXYNotUOTBizszN NVLWXY1mOjRiaB?= M17nbGROW09? MmrRV5VxeHKnc4Pld{BtcWejbnStcYVlcWG2ZXSgRXIuTkxic3nncoFtcW6p MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjdzMESzOkc,OjJ5MUC0N|Y9N2F-
BCK4 MUDGeY5kfGmxbjDBd5NigQ>? MWKxNEDPxE1? MmS2O{Bl[Xm| NHS4b29FVVOR MkfaTY5pcWKrdIOg[ZN1emGmaX;sMY1m\GmjdHXkJJBzd2yrZnXyZZRqd25? NXTacoUyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0OVEyODlpPkK0OFUyOTB7PD;hQi=>
MCF7s NHvZeohHfW6ldHnvckBCe3OjeR?= MYixNEDPxE1? NYH5RnVXPiCmYYnz M1LWcmROW09? MnezTY5pcWKrdIOg[ZN1emGmaX;sMY1m\GmjdHXkJJBzd2yrZnXyZZRqd25? NIi5cms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES1NVExQSd-MkS0OVEyODl:L3G+
PC-3 MXvGeY5kfGmxbjDBd5NigQ>? MmnENVAh|ryP NITpfXU4OiCq M3HDZWROW09? NH\mRoNFd2W|IH7veEBqdmirYnn0JINmdGxicILvcIln\XKjdHnvci=> MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN2NEi2OEc,OjV|NES4OlQ9N2F-
CWR22Rv1 M2\wcGZ2dmO2aX;uJGF{e2G7 M3jwblE2KM7:TR?= M4\v[|I1KGh? NEfvN2FFVVOR NHvxRoVFd2W|IH7veEBi\m[nY4SgeIhmKG[3bHygcIVv\3SqIFHSJIV5eHKnc4Ppc44> NXThfGY5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NVM2PjdpPkKzO|E{PTZ5PD;hQi=>
LNCAP/AR NETIepNCdnSjZ3;ubZN1KGGldHn2bZR6KGG|c3H5 M1vKbmlEPTBiPTCwMlAzOSEQvF2= MoTYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5MUe1OFQoRjJ5N{G3OVQ1RC:jPh?=
MDA-MB-453 NVGzVpZCSW62YXfvcol{fCCjY4Tpeol1gSCjc4PhfS=> Mo\nSWM2OCB;IECuNFQ6KM7:TR?= M3LpbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{GzOVY4Lz5{M{exN|U3PzxxYU6=
LNCAP M3TldGFvfGGpb37pd5Qh[WO2aY\peJkh[XO|YYm= NF35Xnk4OiCq M1LrNmlEPTBiPTCwMlA2KM7:TR?= MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODF7M{KxOUc,OzBzOUOyNVU9N2F-
LNCAP Mm\CRY51[WexbnnzeEBi[3Srdnn0fUBie3OjeR?= M3HsWVczKGh? MWjJR|UxKD1iMD6wPUDPxE1? M3naWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMUmzNlE2Lz5|MEG5N|IyPTxxYU6=
LNCAP Ml7vS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1jUVWdKPTBiPTCwMlEzKM7:TR?= NHSyV2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OECxNVIyQSd-MkiwNVEzOTl:L3G+
LNCAP M1qzd2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NWH5S4dWOyCmYYnz M1XhWGlEPTBiPTCwMlEzPzFizszN M37oO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MES2N|E{Lz5{NkC0OlMyOzxxYU6=
LNCAP MoT4RY51[WexbnnzeEBi[3Srdnn0fUBie3OjeR?= M3XLO|Yh\GG7cx?= NF[0PYVIUTVyIE2gNE4zQSEQvF2= MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDBzMUKxPUc,OjhyMUGyNVk9N2F-
UAS-bla GripTite 293 M4XtU2FvfGGpb37pd5Qh[WO2aY\peJkh[XO|YYm= NGrFfpkyPiC2bzCyOEBp NVTBfVFWUUN3MDC9JFAvOzZzIN88US=> M4XBOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5M{CxN|Y5Lz5{N{OwNVM3QDxxYU6=
mammalian expression system NIfqfYZCdnSjZ3;ubZN1KGGldHn2bZR6KGG|c3H5 MojuNlIhfG9iMkSgbC=> MX3FR|UxKD1iMD60NkDPxE1? MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN6NUWwN{c,Ojh|OEW1NFM9N2F-
VCaP Mn\xS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4LRT|E1PCCq NGHseFBIUTVyIE2gNE43OSEQvF2= M4jR[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUKxOVg3Lz5{NUGyNVU5PjxxYU6=
LNCaP NVjrZWFzSW62YXfvcol{fCCjY4Tpeol1gSCjc4PhfS=> MmfQNkBp NHzMUW1GSzVyIE2gNE46OTVizszN M3;1dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{GzOVY4Lz5{M{exN|U3PzxxYU6=
COS7 M{P2SWFvfGGpb37pd5Qh[WO2aY\peJkh[XO|YYm= Mln1NlQhcA>? NXPYd4psUUN3MDC9JFEvOjZizszN NYjBRoR[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxNVc5QTdpPkK5NVE4QDl5PD;hQi=>
AR LBD mutant MV\BcpRi\2:waYP0JIFkfGm4aYT5JIF{e2G7 NH3yNnA1KGh? NYDhRlJvUUN3MDC9JFEvOzVizszN Ml;hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6MUC1PFkoRjJ5OEGwOVg6RC:jPh?=
LNCAP MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml7OS2k2OCB;IEKuPFgh|ryP M{jmc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkO0NVMxLz5{NU[zOFE{ODxxYU6=
CWR22Rv1 NXnIOGlET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn:0S2k2OCB;IEOuN|Qh|ryP MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ|NEGzNEc,OjV4M{SxN|A9N2F-
LNCAP MULDfZRwfG:6aXPpeJkh[XO|YYm= NGHSU4Q4KGSjeYO= NETO[5lIUTVyIE2gOU4yOiEQvF2= Mn;sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5MUO1OlcoRjJ|N{GzOVY4RC:jPh?=
PC3 NIrLbIVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NX;VR5Q2T0l3MDC9JFkvOTVizszN MlzSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4M{SxN|AoRjJ3NkO0NVMxRC:jPh?=
CWR22Rv1 NIXIO2tE\WyuIIP1dpZqfmGuIHHzd4F6 Mn6xNVQ1KGh? MUjJR|UxKD1iOT63JO69VQ>? MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{MUW4Okc,OjVzMkG1PFY9N2F-
LNCAP M2C1TWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NXLPN5h{QTZiaB?= Ml;CTWM2OCB;IEGxMlQ4KM7:TR?= M2nFXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5M{CxN|Y5Lz5{N{OwNVM3QDxxYU6=
LNCaP-hr Mor3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NYnRcplYOyCmYYnz MkjLTWM2OCB;IEGyMlUh|ryP M1TVWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OEGwOVg6Lz5{N{ixNFU5QTxxYU6=
LNCAP NUfVSJpuSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MY[zJIRigXN? MofQTWM2OCB;IEGyMlUh|ryP NI\PUIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUGxO|g6Pyd-MkmxNVc5QTd:L3G+
LNCaP NUm5fllwSW62YXfvcol{fCCjY4Tpeol1gSCjc4PhfS=> NF:4OXgyPDRiaB?= NYr6T2F{T0l3MDC9JFE5Njh6IN88US=> MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ5Mki5OEc,Ojh{N{K4PVQ9N2F-
LNCaP-AR NV;ZdIM6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NV\KPJMzOTR2IHi= M{DnU2dKPTBiPTCxPE46KM7:TR?= MlHjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkG1PFYoRjJ3MUKxOVg3RC:jPh?=
C4-2B MmPhRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M3LvWVEzKGh? NWDlTWVMUUN3MDC9JFIxNjd5IN88US=> MmLlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5NUi1NVgoRjJ7N{W4OVE5RC:jPh?=
A31 Mn;IS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUHlNGZJPzJiaB?= MlzYS2k2OCB;IEK3MlUh|ryP M{DZZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEGxNlE6Lz5{OECxNVIyQTxxYU6=
22Rv1 MkXRRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M{TzUVk3KGh? MWPJR|UxKD1iM{GuO|Yh|ryP NGiyd|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{OwNVM3QCd-MkezNFE{Pjh:L3G+
22Rv1 NFf2SmhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NUfncowzQTZiaB?= NHLn[ZpKSzVyIE2gN|EvPzZizszN M1;YXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OU[1PFYzLz5{Nkm2OVg3OjxxYU6=
DU145 NEDqd3VCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= M1r5R|k3KGh? M3\5PGlEPTBiPTCzNk4zPyEQvF2= MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzNyMUO2PEc,Ojd|MEGzOlg9N2F-
LNCAP M4LXcWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NEP2NXE4OiCq MXjJR|UxKD1iM{OuPFQh|ryP Mon3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2NEixN|koRjJ7NES4NVM6RC:jPh?=
CW22Rv1 MYDBcpRi\2:waYP0JIFkfGm4aYT5JIF{e2G7 MoWzO|IhcA>? MnfaTWM2OCB;IEO1Mlc2KM7:TR?= M2W5NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkeyPFk1Lz5{OEK3Nlg6PDxxYU6=
22Rv1 M3rSbGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 M4LYTlczKGh? MXrJR|UxKD1iM{[uOlYh|ryP NVv0UJltRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OFgyOzlpPkK5OFQ5OTN7PD;hQi=>
22Rv1 NWTzSYVpSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NVTwV4lmOTJiaB?= M4Tvd2lEPTBiPTCzOk43PiEQvF2= M2q2XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{W4OVE5Lz5{OUe1PFUyQDxxYU6=
LNCAP MnLXRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NXPZfld3OTJiaB?= MXjJR|UxKD1iNEKuN|ch|ryP NWiwUHRyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3OVg2OThpPkK5O|U5PTF6PD;hQi=>
DU145 NGPiSIJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= M{ftTVMh\GG7cx?= NHrafoxKSzVyIE2gOFYvOSEQvF2= NHrMO209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{ixNFU5QSd-Mke4NVA2QDl:L3G+
DU145 NYjZWlA6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MYizJIRigXN? M1r3OWlEPTBiPTC0Ok4yKM7:TR?= Mn7SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzMUe4PVcoRjJ7MUG3PFk4RC:jPh?=
Assay
Methods Test Index PMID
Western blot AR / ERG / NOTCH1 / PSA / Cleaved PARP1 / Cleaved caspase 7 AR-FL / AR-v7 / pAR(S213) / pAkt(S473) / pMdm2(S166) CXCR7 28607007 26378044 29277895
Growth inhibition assay Cell proliferation 28115200
Immunofluorescence AR pAKT(S473) CXCR7 27588408 29277895
ELISA osteoprotegerin 27015557
体内研究 Enzalutamide处理携带LNCaP/AR移植瘤的阉割雄鼠,按鼠体重,每千克处理10mg MDV310,可诱导肿瘤的明显退化。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[3]
  • AR受体实验:

    在抗激素的前列腺癌细胞系中通过人工AR反应报告分子系统测定Enzalutamide。在这个系统中,前列腺癌LNCaP细胞稳定表达AR,表达的AR水平比体内自身产生的AR水平高5倍多。外界合成的AR和体内自身产生的AR有着相似的特性,都能稳定与合成的雄激素R1881作用。AR过量表达的细胞也能含有AR反应报告分子,这些细胞的报告分子活性显示抗激素前列腺癌的特性。在含100 pM R1881时测定Enzalutamide的抗性。LNCaP细胞供养在含有10%胎牛血清的Iscove's培养基中。在用Enzalutamide处理的前两天,细胞在含活性炭处理的胎牛血清(CS-FBS)Iscove's培养基中生长,用于除去雄激素。细胞在培养基上分裂和生长,培养基含有10% CS-FBS,100 pM R1881,及增加浓度的Enzalutamide。温育两天后,测定报告分子活性。

细胞实验:[1]
  • Cell lines: LNCaP或LNCaP/AR细胞
  • Concentrations: 10 μM 左右
  • Incubation Time: 1-4天
  • Method: 用DMSO稀释Enzalutamide。LNCaP或LNCaP/AR细胞(104细胞/每孔)缺乏雄激素,在含有5-10%活性炭处理的血清培养基上生长3到5天。然后在5-10%活性炭处理的血清培养基中加入不同浓度(1到10000 nM)Enzalutamide处理细胞。
动物实验:[1]
  • Animal Models: 雄激素非依赖性LNCaP/HR移植瘤雄性SCID鼠
  • Dosages: 10 mg/kg
  • Administration: 每天饲喂处理

溶解度(25°C)

体外

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 464.44
化学式

C21H16F4N4O2S

CAS号 915087-33-1
储存条件 3年 -20°C 粉状
2年 -80°C 溶于溶剂

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量 浓度 体积 分子量

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05191017 Not yet recruiting Drug: NUV-422|Drug: Enzalutamide Prostate Cancer|Prostatic Cancer|Cancer of Prostate|Cancer of the Prostate|Prostate Neoplasm|Castrate Resistant Prostate Cancer|Castration Resistant Prostatic Cancer|Castration Resistant Prostatic Neoplasms Nuvation Bio Inc. April 2022 Phase 1|Phase 2
NCT05081193 Not yet recruiting Drug: Testosterone Undecanoate|Drug: Enzalutamide Prostate Cancer|Castration-resistant Prostate Cancer|Metastatic Castration-resistant Prostate Cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Clarus Therapeutics February 15 2022 Phase 2
NCT04335682 Recruiting Drug: Darolutamide|Drug: Enzalutamide Metastatic Prostate Cancer|Prostate Cancer Metastatic|Prostate Cancer|Castrate Resistant Prostate Cancer Alliance Foundation Trials LLC.|Bayer August 17 2021 Phase 2
NCT04655365 Not yet recruiting Drug: Enzalutamide capsule Prostate Cancer CHU de Quebec-Universite Laval|Astellas Pharma Europe Ltd. January 4 2021 Phase 2
NCT04456049 Not yet recruiting Drug: Enzalutamide COVID-19 Infection Ricardo Pereira Mestre|Oncology Institute of Southern Switzerland|Institute of Oncology Research|Institute for Research in Biomedicine|Ente Ospedaliero Cantonale Bellinzona July 2020 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们